Literature DB >> 17532008

Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice.

Hong-Bo Xiao1, Zhi-Chun Yang, Su-Jie Jia, Nian-Sheng Li, De-Jian Jiang, Xiao-Hong Zhang, Ren Guo, Zhi Zhou, Han-Wu Deng, Yuan-Jian Li.   

Abstract

Previous investigations have shown that the level of asymmetric dimethylarginine (ADMA) was increased in hypercholesterolemic animal and humans, and the decreased erythrocyte deformability has been suggested to be a factor contributing to atherogenesis. In the present study, we investigated the effect of ADMA, endogenous or exogenous, on atherogenesis and erythrocyte deformability in apolipoprotein E deficient (ApoE-/-) mice. On a regular chow diet, ApoE-/- mice or C57BL/6 J mice at 12 weeks of age were treated with ADMA (5 mg/kg/day) for 4 weeks. Atherosclerotic lesion area, erythrocyte deformability, plasma lipids and asymmetric dimethylarginine (ADMA) level were determined. Plasma concentrations of triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), total cholesterol (TC), ADMA, and atherosclerotic lesion area were significantly increased, and the level of plasma high-density lipoprotein-cholesterol (HDL-C), erythrocyte deformability in ApoE-/- mice were markedly decreased compared with that of C57BL/6J mice (P<0.05 or P<0.01). Exogenous ADMA treatment increased the plasma TG level, produced atherosclerotic lesions, and decreased erythrocyte deformability in C57BL/6J mice (P<0.05 or P<0.01). Treatment with exogenous ADMA further increased the plasma TG level and lesion areas, and decreased erythrocyte deformability in ApoE-/- mice. In vitro, exogenous ADMA caused a decrease of erythrocyte deformability in a concentration-dependent manner, and the effect of ADMA was reversed by L-arginine. The present results suggest that endogenous ADMA is an important contributor to the development of atherosclerosis and that reduction of erythrocyte deformability and impaired endothelial function induced by ADMA may be an important factor facilitating atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532008     DOI: 10.1016/j.lfs.2007.04.019

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.

Authors:  Johannes Jacobi; Renke Maas; Arturo J Cardounel; Michaela Arend; Arthur J Pope; Nada Cordasic; Juliane Heusinger-Ribeiro; Dorothee Atzler; Joachim Strobel; Edzard Schwedhelm; Rainer H Böger; Karl F Hilgers
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

2.  Asymmetric dimethylarginine triggers macrophage apoptosis via the endoplasmic reticulum stress pathway.

Authors:  Dan Hong; Hai-Chao Gao; Xiang Wang; Ling-Fang Li; Chuan-Chang Li; Ying Luo; Kang-Kai Wang; Yong-Ping Bai; Guo-Gang Zhang
Journal:  Mol Cell Biochem       Date:  2014-09-11       Impact factor: 3.396

3.  Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study.

Authors:  Ibrahim Musa Yola; Carlee Moser; Meredith S Duncan; Edzard Schwedhelm; Dorothee Atzler; Renke Maas; Juliane Hannemann; Rainer H Böger; Ramachandran S Vasan; Vanessa Xanthakis
Journal:  PLoS One       Date:  2021-09-07       Impact factor: 3.240

4.  Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases.

Authors:  Xiaoyu Liu; John Fassett; Yidong Wei; Yingjie Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.